Fundraising Fox

Immitra Bio

Zürich, CH · Founded 2024 · 6 employees on LinkedIn · 5 known investors

Immitra Bio develops an in-vivo stem cell therapy platform designed to treat rare genetic diseases, particularly severe inherited red blood cell disorders, by replacing complex transplants with single off-the-shelf treatments. The company is an ETH Zürich spin-off focused on precision medicine and gene editing approaches for genetic disease intervention.

BiotechDeep TechMedical Devices

Founders & leadership

JN
Jan NelisinCEO

Investors · 5

Kickfund✓ verifiedZurich · $950K
OCCIDENT✓ verifiedMunich
another.vc✓ verifiedMülheim an der Ruhr · $270K
Backbone Ventures✓ verifiedZurich · $330K – $440K
Venture Kick✓ verifiedSchlieren-Zürich

Frequently asked questions

What does Immitra Bio do?
Immitra Bio develops an in-vivo stem cell therapy platform designed to treat rare genetic diseases, particularly severe inherited red blood cell disorders, by replacing complex transplants with single off-the-shelf treatments. The company is an ETH Zürich spin-off focused on precision medicine and gene editing approaches for genetic disease intervention.
Who are Immitra Bio's investors?
Immitra Bio's investors include Kickfund, OCCIDENT, another.vc, Backbone Ventures, Venture Kick.
Where is Immitra Bio headquartered?
Immitra Bio is headquartered in Zürich, CH.